Since the IL-6-Jak1-Stat3 pathway is a robust inducer of PC growth and metastasis, simultaneous suppression of Jak1-Stat3 is a desirable off-target effect of the Jak2 inhibitors in therapeutic applications for PC, which would expectedly lead to greater responsiveness of advanced PC to Jak2 inhibitor treatment. The gene discussed is JAK1; the disease is pachyonychia congenita.